^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) + RMC-4550 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1057 - Combination of the KRASG12C inhibitor sotorasib with targeted agents improves anti-tumor efficacy in KRAS p.G12C cancer models
Published date:
03/10/2021
Excerpt:
In efficacy studies using the NCI-H358 xenograft model, significantly enhanced anti-tumor activity was observed with a minimally efficacious dose of sotorasib in combination with afatinib, RMC-4550, or a CDK4/6 inhibitor (palbociclib). Furthermore, enhanced anti-tumor activity was observed with sotorasib in combination with a MEK inhibitor or with the anti-EGFR monoclonal antibody panitumumab in a CRC KRAS p.G12C PDX model.
